Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 crossover PK study of KA-2301 vs ReQuip CR in healthy Japanese males
jRCT2051250084Phase 1Completed
- Sponsor
- Alfresa
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of ropinirole (3 arms), sponsored by Alfresa. Primary endpoints: Plasma pharmacokinetic parameters, Adverse events and 3 more. Started Aug 2025; status: completed.
02
Drugs
ropinirole
Beyond the preview
Go deeper on jRCT2051250084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250084.